Evaluation of short-acting Beta-2-agonist prescriptions and associated clinical outcomes: Findings from the SABA use IN Asthma (SABINA) study in Asia

Background: The extent of short-acting Beta-2-agonist (β2-agonist) (SABA) use across Asian countries is not well documented. As part of the SABA use IN Asthma (SABINA) III study, we assessed SABA prescriptions and clinical outcomes in patients with asthma from Asia. Methods: This cross-sectional study recruited patients (aged ≥12 years) with asthma from 8 Asian countries. Data on disease characteristics and asthma treatments were collected using electronic case report forms. Patients were classified by practice type (primary or specialist care) and investigator-defined asthma severity (per Glo... Mehr ...

Verfasser: Hao-Chien Wang, MD PhD
Susanthy Djajalaksana, MD
Latha Sharma, MD
Theerakorn Theerakittikul, MD
Hui Fang Lim, MBBS
Kwang Ha Yoo, MD
Andrea Ban Yu-Lin, MMED
Dina V. Diaz, MD
Lala Yang, Master
Maarten J.H.I. Beekman, MD
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Reihe/Periodikum: World Allergy Organization Journal, Vol 16, Iss 10, Pp 100823- (2023)
Verlag/Hrsg.: Elsevier
Schlagwörter: Asia / Asthma / Prescriptions / Public health / Adrenergic beta-2 receptor agonists / Immunologic diseases. Allergy / RC581-607
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29234270
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.1016/j.waojou.2023.100823